Posts tagged as: FDA meeting back to homepage
 |
Cellceutix Selects Dr. Reddy’s for Manufacturing of New Psoriasis Drug(0) Beverly, Massachusetts-based Cellceutix Corporation (OTCBB: CTIX) reported this morning that they have chosen Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) to synthesize and manufacture Prurisol, Cellceutix’s lead anti-psoriasis drug candidate. Cellceutix will be advancing Prurisol into Phase II/III clinical trials under guidance from the Food and Drug Administration that the drug qualifies for a 505(b)(2) designation. Read More |
 |
FDA Gives Nod to Cellceutix for 505(b)(2) Eligibility for Psoriasis Drug(0) Cellceutix Corporation (OTCBB: CTIX) (the “Company”), a biopharmaceutical company focused on discovering small molecule drugs to treat unmet medical conditions, including drug-resistant cancers and autoimmune diseases, reports today that it has participated in a meeting with the U.S. Food and Drug Administration (“FDA”) pertaining to the Company’s psoriasis compound, Prurisol™. As previously disclosed on April 16, 2012, the Company had Read More |
|
Cellceutix to Meet with FDA on New Psoriasis Drug(0) This one day might be the story called “The Little Biotech That Could”. Cellceutix Corp. (OTCBB: CTIX) has a pipeline of eight drugs with three that have already begun clinical trials (one for cancer, one for psoriasis and one for autism). The flagship drug, Kevetrin™ is being developed as an anti-cancer drug with clinical trials slated to be hosted at the vaunted Dana-Farber Cancer Center. Read More |
OTCBB News
read more
Stay Informed
Dana-Farber to Host Cellceutix Trials
Diabetes Rate Growing Exponentially
According to the International Diabetes Federation, more than 500 million people will be diagnosed with diabetes in the next two decades, a more than 50 percent increase from today. Technologies are available presently to help manage the frequency, complications and costs associated with diabetes. Read the complete article to learn more.
